Defining the disease course of TNFα blockers-associated Multiple Sclerosis

Matteo Lucchini, Assunta Bianco, Paolo Calabresi, Massimiliano Mirabella, Guido Maria Giuffre', Viviana Nociti, Chiara De Fino

Research output: Contribution to journalArticlepeer-review


Tumour Necrosis Factor alpha (TNFalpha) blockers are common and effective treatments for several autoimmune diseases but can be associated with neuroinflammatory events. We describe the disease course of ten patients who developed CNS demyelinating events while exposed to TNFalpha blockers. We divided them into two groups: eight patients with Relapsing Multiple Sclerosis and two isolated optic neuritis. In our cohort, TNFalpha blockers-associated Multiple Sclerosis does not seem to be associated with a more aggressive course and can be managed with MS-specific DMTs, chosen considering the clinical course and the concomitant autoimmune disease. Our findings need confirmation in larger cohorts to further characterize the disease course of TNFalpha blockers-associated Multiple Sclerosis.
Original languageEnglish
Pages (from-to)577525-N/A
JournalJournal of Neuroimmunology
Publication statusPublished - 2021


  • Central nervous system (CNS) inflammatory disorders
  • Demyelinating disorders
  • Multiple sclerosis
  • Rheumatological disorders
  • TNFα
  • Tumour necrosis factor alpha blockers


Dive into the research topics of 'Defining the disease course of TNFα blockers-associated Multiple Sclerosis'. Together they form a unique fingerprint.

Cite this